Resverlogix Corp (RVXCF) 1.5300 $RVXCF
Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference
PR Newswire - Thu Sep 10, 6:00AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company"
(TSX:RVX) is pleased to announce that Mr. Donald McCaffrey, president and chief executive officer of Resverlogix Corp. will be presenting today at the Rodman & Renshaw 17th Annual Global Investment Conference at 10:25 am EDT in Louis XVI A (2nd floor, St. Regis Hotel, New York). The presentation will be available via webcast at: http://wsw.com/webcast/rrshq25/rvxhttp://wsw....rshq25/rvx
RVX.TO: 1.91 (-0.16)
International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"
PR Newswire - Tue Aug 04, 6:30AM CDT
Professor Kausik Ray to Chair Clinical Steering Committee for Landmark Epigenetic BET Inhibition Trial
RVX.TO: 1.91 (-0.16)
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Wed Jul 29, 11:30AM CDT
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 3.29 (-0.01), KNMD: (), VTAE: 14.32 (+0.51), LLY: 81.80 (+0.96), OMER: 14.12 (+0.33), JNJ: 92.93 (+0.21), ISIS: 54.08 (+1.07), OPK: 10.09 (-0.46), GILD: 109.63 (+2.38), AZN: 33.30 (+0.02), MRK: 52.09 (-0.63), CCXI: 6.40 (unch), VBLT: 5.24 (-0.09), NVS: 96.55 (+0.28)
Shenzhen Hepalink Pharmaceutical Co., Ltd. Announces Investment in Resverlogix Corp.
Marketwired - Fri Jul 24, 11:21AM CDT
Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink" is pleased to announce that on July 20, 2015, Hepalink acquired 13,270,000 units ("Units" of Resverlogix Corp. ("RVX" by way of a private placement (the "Private Placement" at a price of Cdn.$2.67 per Unit, for an aggregate purchase price of Cdn.$35,430,900. Each Unit consists of one common share of RVX ("Common Share" plus 0.075358 of a common share purchase warrant of RVX ("Warrant" expiring five years after the closing of the Private Placement. Each whole Warrant entitles Hepalink to purchase one Common Share at an exercise price of Cdn.$2.67. The Private Placement was part of a larger offering of Units pursuant to which RVX issued 18,870,000 Units for aggregate proceeds of Cdn$50,382,900 (the "Offering" .
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics Pipeline Report 2015 - 22 Companies & 30 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63tfvw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - KunWha Pharmaceutical Co., Ltd. - MedImmune, LLC - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - RegenoCELL Therapeutics, Inc. - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. Drug Profiles - (cilostazol organic nitrate) ER - AEM-28 - ALD-301 - Annexin A-5 - CVBT-141C - DVC1-0101 - ELS-140 - Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - MEDI-6012 - Mesenchymal Stem Cells - MGN-6114 - MultiGeneAngio - MultiGeneGraft - MultiStem - O-304 - PDA-002 - REC-03 - rivaroxaban - RVX-208 - sarpogrelate SR - selegiline Antiplatelet Drugs - sodium nitrite SR - Stem Cell Therapy for Cardiovascular Diseases - SYN-20112312RU - ticagrelor - transcrocetinate sodium - TXA-127 - VM-202 - vonapanitase For more information visit http://www.researchandmarkets.com/research/63tfvw/peripheral
AZN: 33.30 (+0.02), ATHX: 1.20 (-0.02), PRTO: 14.91 (+0.19), CELGZ: 1.93 (+0.07)
Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital
PR Newswire Europe - Tue Jul 21, 8:12AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.91 (-0.16)
Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, H1 2015 - 28 Companies & 42 Drug Profiles
M2 - Thu Jul 09, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/58mtw9/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AFFiRiS AG - Angion Biomedica Corp. - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Celtic Biotech, Ltd. - Concert Pharmaceuticals, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Multi Gene Vascular Systems Ltd - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Quark Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/58...nic_kidney
OPK: 10.09 (-0.46), ICPT: 197.48 (+4.66), LLY: 81.80 (+0.96), CNCE: 19.27 (+0.68), XLRN: 33.62 (+1.44)
Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink
PR Newswire - Wed Jul 08, 6:00AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.91 (-0.16)
Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement
PR Newswire - Tue Jun 30, 4:39PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.91 (-0.16)
Resverlogix to Present at the 2015 Bio International Convention
PR Newswire - Wed Jun 17, 6:30AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.91 (-0.16)
Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA
PR Newswire - Mon Jun 08, 10:35AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.91 (-0.16)
Restenosis Pipeline Review 2015 - 7 Companies & 14 Drug Profiles
M2 - Thu May 21, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xq5hhl/restenosis) has announced the addition of the "Restenosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - advanceCor GmbH - CSPC Pharmaceutical Group Limited - CytoTools AG - Resverlogix Corp. - Shire Plc - Viron Therapeutics, Inc. - XBiotech USA, Inc. Drug Profiles - Annexin A-5 - Antibody Conjugate for Restenosis - butylphthalide - COR-3 - CV-18C3 - HMW-02Ak - HMW-02Ap - HO-3867 - LDH-DDART - PVS-10200 - Small Molecules for Cardiovascular Diseases - Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - VAN 10-4 - VT-214 For more information visit http://www.researchandmarkets.com/research/xq5hhl/restenosis
SHPG: 223.00 (-2.43)
Week In Review: WuXi PharmaTech Announces $3.3 Billion Go-Private Offer
ChinaBio Today - at Seeking Alpha - Sun May 03, 4:57AM CDT
Deals and Financings WuXi PharmaTech (NYSE: WX ), China's largest CRO/CMO, announced a surprise privatization offer of $46 per ADS from Dr. Ge Li, the company's founder, chairman and CEO, and Ally Bridge Group Capital Partners. Before the offer,...
CO: 6.39 (-0.01), WX: 42.90 (-0.10)
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement
CNW Group - Mon Apr 27, 6:00AM CDT
The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million
RVX.TO: 1.91 (-0.16)
Week In Review: aTyr Pharma To Raise $86 Million In IPO
ChinaBio Today - at Seeking Alpha - Sun Apr 12, 5:07AM CDT
Deals and Financings aTyr Pharma (Pending: LIFE ), a San Diego-Hong Kong clinical stage biotherapeutics company, filed to conduct an $86 million IPO on the Nasdaq exchange (see story ). The company develops Physiocrine-based therapeutics to...
LIFE: 16.96 (-1.47), CYTX: 0.44 (-0.04)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 315.37 (+2.75), SPHS: 0.85 (+0.03), ADMS: 19.93 (+0.50), TKMR: 10.83 (+0.58), CBYL: 5.27 (+0.13), HPTX: 45.99 (+0.02), QURE: 27.50 (+0.78), SHPG: 223.00 (-2.43), SRPT: 35.94 (+1.49), HZNP: 28.99 (+0.41), GALE: 1.70 (-0.01), JUNO: 41.58 (+1.15), ABBV: 59.35 (-0.23), CBMG: 22.85 (-0.01), ARNA: 2.86 (+0.15), EXEL: 5.91 (+0.04), ADXS: 16.51 (+0.55), PTLA: 49.77 (+3.03), BMY: 59.22 (+0.47), OCUL: 16.64 (-0.61), NVO: 56.95 (+0.37), DVA: 75.00 (+0.36), HALO: 18.08 (+0.35), GILD: 109.63 (+2.38), MRK: 52.09 (-0.63), AZN: 33.30 (+0.02), ALXN: 171.93 (+0.28), NVS: 96.55 (+0.28)
Analysis Of The Science Behind RVX-208
Bjarke Krysel Christensen - at Seeking Alpha - Wed Apr 08, 8:25AM CDT
AZN: 33.30 (+0.02)
Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference
PR Newswire - Thu Sep 10, 6:00AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company"
(TSX:RVX) is pleased to announce that Mr. Donald McCaffrey, president and chief executive officer of Resverlogix Corp. will be presenting today at the Rodman & Renshaw 17th Annual Global Investment Conference at 10:25 am EDT in Louis XVI A (2nd floor, St. Regis Hotel, New York). The presentation will be available via webcast at: http://wsw.com/webcast/rrshq25/rvxhttp://wsw....rshq25/rvx RVX.TO: 1.91 (-0.16)
International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"
PR Newswire - Tue Aug 04, 6:30AM CDT
Professor Kausik Ray to Chair Clinical Steering Committee for Landmark Epigenetic BET Inhibition Trial
RVX.TO: 1.91 (-0.16)
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Wed Jul 29, 11:30AM CDT
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 3.29 (-0.01), KNMD: (), VTAE: 14.32 (+0.51), LLY: 81.80 (+0.96), OMER: 14.12 (+0.33), JNJ: 92.93 (+0.21), ISIS: 54.08 (+1.07), OPK: 10.09 (-0.46), GILD: 109.63 (+2.38), AZN: 33.30 (+0.02), MRK: 52.09 (-0.63), CCXI: 6.40 (unch), VBLT: 5.24 (-0.09), NVS: 96.55 (+0.28)
Shenzhen Hepalink Pharmaceutical Co., Ltd. Announces Investment in Resverlogix Corp.
Marketwired - Fri Jul 24, 11:21AM CDT
Shenzhen Hepalink Pharmaceutical Co., Ltd. ("Hepalink"
is pleased to announce that on July 20, 2015, Hepalink acquired 13,270,000 units ("Units" of Resverlogix Corp. ("RVX" by way of a private placement (the "Private Placement" at a price of Cdn.$2.67 per Unit, for an aggregate purchase price of Cdn.$35,430,900. Each Unit consists of one common share of RVX ("Common Share" plus 0.075358 of a common share purchase warrant of RVX ("Warrant" expiring five years after the closing of the Private Placement. Each whole Warrant entitles Hepalink to purchase one Common Share at an exercise price of Cdn.$2.67. The Private Placement was part of a larger offering of Units pursuant to which RVX issued 18,870,000 Units for aggregate proceeds of Cdn$50,382,900 (the "Offering" . Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics Pipeline Report 2015 - 22 Companies & 30 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/63tfvw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - KunWha Pharmaceutical Co., Ltd. - MedImmune, LLC - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - RegenoCELL Therapeutics, Inc. - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. Drug Profiles - (cilostazol organic nitrate) ER - AEM-28 - ALD-301 - Annexin A-5 - CVBT-141C - DVC1-0101 - ELS-140 - Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - MEDI-6012 - Mesenchymal Stem Cells - MGN-6114 - MultiGeneAngio - MultiGeneGraft - MultiStem - O-304 - PDA-002 - REC-03 - rivaroxaban - RVX-208 - sarpogrelate SR - selegiline Antiplatelet Drugs - sodium nitrite SR - Stem Cell Therapy for Cardiovascular Diseases - SYN-20112312RU - ticagrelor - transcrocetinate sodium - TXA-127 - VM-202 - vonapanitase For more information visit http://www.researchandmarkets.com/research/63tfvw/peripheral
AZN: 33.30 (+0.02), ATHX: 1.20 (-0.02), PRTO: 14.91 (+0.19), CELGZ: 1.93 (+0.07)
Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital
PR Newswire Europe - Tue Jul 21, 8:12AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.91 (-0.16)
Chronic Kidney Disease (Chronic Renal Failure) Pipeline Review, H1 2015 - 28 Companies & 42 Drug Profiles
M2 - Thu Jul 09, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/58mtw9/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AFFiRiS AG - Angion Biomedica Corp. - Astellas Pharma Inc. - Bayer AG - Bio-inRen - Boryung Pharmaceutical Co., Ltd. - Celtic Biotech, Ltd. - Concert Pharmaceuticals, Inc. - Eli Lilly and Company - Evotec AG - Intercept Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Multi Gene Vascular Systems Ltd - Nippon Zoki Pharmaceutical Co., Ltd. - OPKO Health, Inc. - Otsuka Holdings Co., Ltd. - Prolong Pharmaceuticals - ProMetic Life Sciences Inc. - Quark Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - Red Glead Discovery AB - Resverlogix Corp. - Sphaera Pharma Pvt. Ltd. - Stelic Institute & Co. - Toray Industries, Inc. - VBS Pharmaceuticals - Vicore Pharma AB For more information visit http://www.researchandmarkets.com/research/58...nic_kidney
OPK: 10.09 (-0.46), ICPT: 197.48 (+4.66), LLY: 81.80 (+0.96), CNCE: 19.27 (+0.68), XLRN: 33.62 (+1.44)
Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink
PR Newswire - Wed Jul 08, 6:00AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.91 (-0.16)
Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement
PR Newswire - Tue Jun 30, 4:39PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.91 (-0.16)
Resverlogix to Present at the 2015 Bio International Convention
PR Newswire - Wed Jun 17, 6:30AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.91 (-0.16)
Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA
PR Newswire - Mon Jun 08, 10:35AM CDT
TSX Exchange Symbol: RVX
RVX.TO: 1.91 (-0.16)
Restenosis Pipeline Review 2015 - 7 Companies & 14 Drug Profiles
M2 - Thu May 21, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xq5hhl/restenosis) has announced the addition of the "Restenosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - advanceCor GmbH - CSPC Pharmaceutical Group Limited - CytoTools AG - Resverlogix Corp. - Shire Plc - Viron Therapeutics, Inc. - XBiotech USA, Inc. Drug Profiles - Annexin A-5 - Antibody Conjugate for Restenosis - butylphthalide - COR-3 - CV-18C3 - HMW-02Ak - HMW-02Ap - HO-3867 - LDH-DDART - PVS-10200 - Small Molecules for Cardiovascular Diseases - Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - VAN 10-4 - VT-214 For more information visit http://www.researchandmarkets.com/research/xq5hhl/restenosis
SHPG: 223.00 (-2.43)
Week In Review: WuXi PharmaTech Announces $3.3 Billion Go-Private Offer
ChinaBio Today - at Seeking Alpha - Sun May 03, 4:57AM CDT
Deals and Financings WuXi PharmaTech (NYSE: WX ), China's largest CRO/CMO, announced a surprise privatization offer of $46 per ADS from Dr. Ge Li, the company's founder, chairman and CEO, and Ally Bridge Group Capital Partners. Before the offer,...
CO: 6.39 (-0.01), WX: 42.90 (-0.10)
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement
CNW Group - Mon Apr 27, 6:00AM CDT
The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million
RVX.TO: 1.91 (-0.16)
Week In Review: aTyr Pharma To Raise $86 Million In IPO
ChinaBio Today - at Seeking Alpha - Sun Apr 12, 5:07AM CDT
Deals and Financings aTyr Pharma (Pending: LIFE ), a San Diego-Hong Kong clinical stage biotherapeutics company, filed to conduct an $86 million IPO on the Nasdaq exchange (see story ). The company develops Physiocrine-based therapeutics to...
LIFE: 16.96 (-1.47), CYTX: 0.44 (-0.04)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 315.37 (+2.75), SPHS: 0.85 (+0.03), ADMS: 19.93 (+0.50), TKMR: 10.83 (+0.58), CBYL: 5.27 (+0.13), HPTX: 45.99 (+0.02), QURE: 27.50 (+0.78), SHPG: 223.00 (-2.43), SRPT: 35.94 (+1.49), HZNP: 28.99 (+0.41), GALE: 1.70 (-0.01), JUNO: 41.58 (+1.15), ABBV: 59.35 (-0.23), CBMG: 22.85 (-0.01), ARNA: 2.86 (+0.15), EXEL: 5.91 (+0.04), ADXS: 16.51 (+0.55), PTLA: 49.77 (+3.03), BMY: 59.22 (+0.47), OCUL: 16.64 (-0.61), NVO: 56.95 (+0.37), DVA: 75.00 (+0.36), HALO: 18.08 (+0.35), GILD: 109.63 (+2.38), MRK: 52.09 (-0.63), AZN: 33.30 (+0.02), ALXN: 171.93 (+0.28), NVS: 96.55 (+0.28)
Analysis Of The Science Behind RVX-208
Bjarke Krysel Christensen - at Seeking Alpha - Wed Apr 08, 8:25AM CDT
AZN: 33.30 (+0.02)
